LAVA Therapeutics (NASDAQ:LVTX) Downgraded by Leerink Partnrs to “Hold”

Leerink Partnrs cut shares of LAVA Therapeutics (NASDAQ:LVTX) from a strong-buy rating to a hold rating in a research note issued to investors on Thursday,Zacks.com reports.

A number of other equities research analysts have also recently issued reports on LVTX. Citizens Jmp cut LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. Leerink Partners reiterated a “market perform” rating and issued a $2.00 price objective (down from $11.00) on shares of LAVA Therapeutics in a research report on Thursday. Finally, JMP Securities restated a “market perform” rating and issued a $6.00 target price on shares of LAVA Therapeutics in a research report on Wednesday. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $4.67.

LAVA Therapeutics Price Performance

Shares of NASDAQ LVTX opened at $1.20 on Thursday. LAVA Therapeutics has a 12-month low of $1.15 and a 12-month high of $6.47. The stock’s 50 day simple moving average is $1.70 and its 200 day simple moving average is $1.84.

Institutional Trading of LAVA Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in LVTX. XTX Topco Ltd bought a new stake in LAVA Therapeutics during the second quarter worth approximately $55,000. Pathway Financial Advisors LLC increased its position in shares of LAVA Therapeutics by 70.8% during the 3rd quarter. Pathway Financial Advisors LLC now owns 102,500 shares of the company’s stock valued at $170,000 after purchasing an additional 42,500 shares during the period. Finally, Virtu Financial LLC bought a new stake in shares of LAVA Therapeutics in the 3rd quarter worth $32,000.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.